James A Geraghty insider trades: Pieris Pharmaceuticals (PIRS) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where James reports to the SEC
and 2 more companies
Open-market buys and sales
25 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Aug 7, 2024 | PIRS | ↑ Buy | 1 | $1.00 | $1 | Direct | Oct 28, 2024 (82d) |
| Jun 28, 2021 | FULC | ↑ Buy | 10,000 | $9.16 | $92K | Direct | Jun 29, 2021 (1d) |
| Sep 10, 2018 | VYGR | ↑ Buy | 3,000 | $19.39 | $58K | Direct | Sep 12, 2018 (2d) |
| Aug 17, 2018 | VYGR | ↑ Buy | 3,000 | $18.31 | $55K | Direct | Aug 21, 2018 (4d) |
| Aug 7, 2018 | IDRA | ↑ Buy | 10,000 | $5.58 | $56K | Direct | Aug 8, 2018 (1d) |
| May 15, 2018 | PIRS | ↑ Buy | 10,000 | $5.75 | $58K | Direct | May 16, 2018 (1d) |
| Aug 17, 2017 | PIRS | ↑ Buy | 10,000 | $4.82 | $48K | Direct | Aug 17, 2017 (0d) |
| Mar 17, 2017 | JNP | ↑ Buy | 2,000 | $4.82 | $10K | Direct | Mar 20, 2017 (3d) |
| Sep 13, 2016 | JNP | ↑ Buy | 2,000 | $5.96 | $12K | Direct | Sep 14, 2016 (1d) |
| Aug 23, 2016 | JNP | ↑ Buy | 7,000 | $5.96 | $42K | Direct | Aug 24, 2016 (1d) |
| May 13, 2016 | IDRA | ↑ Buy | 10,000 | $1.34 | $13K | Direct | May 16, 2016 (3d) |
| Nov 17, 2015 | JNP | ↑ Buy | 8,000 | $11.75 | $94K | Direct | Nov 19, 2015 (2d) |
| Aug 6, 2015 | JNP | ↑ Buy | 12,000 | $10.46 | $126K | Direct | Aug 10, 2015 (4d) |
| Jun 1, 2015 | JNP | ↑ Buy | 20,550 | $8.38 | $172K | Direct | Jun 2, 2015 (1d) |
| May 27, 2014 | IDRA | ↑ Buy | 10,000 | $2.65 | $27K | Direct | May 29, 2014 (2d) |
| Dec 6, 2013 | IDRA | ↑ Buy | 40,000 | $2.72 | $109K | Direct | Dec 9, 2013 (3d) |
| Sep 16, 2013 | IDRA | ↑ Buy | 60,000 | $1.90 | $114K | Direct | Sep 16, 2013 (0d) |
| Aug 19, 2013 | IDRA | ↑ Buy | 300,000 | $1.75 | $525K | Direct | Aug 20, 2013 (1d) |
| Jun 11, 2010 | GENZ | ↓ Sell | 1,000 | $48.81 | $49K | Direct | Jun 15, 2010 (4d) |
| May 25, 2010 | GENZ | ↓ Sell | 2,329 | $45.59 | $106K | Direct | May 26, 2010 (1d) |
| Nov 6, 2009 | GENZ | ↓ Sell | 36,875 | $52.07 | $1.9M | Direct | Nov 10, 2009 (4d) |
| Dec 14, 2007 | GTCB | ↑ Buy | 10,000 | $0.87 | $9K | Direct | Dec 17, 2007 (3d) |
| Sep 29, 2006 | GTCB | ↑ Buy | 2,621 | $1.24 | $3K | Direct | Nov 16, 2006 (48d) |
| Nov 11, 2005 | GTCB | ↑ Buy | 3,000 | $1.61 | $5K | Direct | Nov 15, 2005 (4d) |
| May 16, 2005 | GTCB | ↑ Buy | 3,000 | $1.32 | $4K | Direct | May 16, 2005 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About James A Geraghty's insider trades
James A Geraghty is a director at Pieris Pharmaceuticals (PIRS). Since May 16, 2005, James has reported 22 open-market purchases worth $1.6M and 3 sales worth $2.1M on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (76 filings), shares returned to the company (4 filings), option exercises (3 filings), other transactions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every PIRS insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.